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OBJECTIVE—Glucocorticoids (GCs) are regarded as diabetogenic because they impair in-
sulinsensitivityandislet-cellfunction.Thisstudyassessedwhethertreatmentwiththeglucagon-
like peptide receptor agonist (GLP-1 RA) exenatide (EXE) could prevent GC-induced glucose
intolerance.
RESEARCH DESIGN AND METHODS—A randomized, placebo-controlled, double-
blind, crossover study in eight healthy men (age: 23.5 [20.0–28.3] years; BMI: 26.4 [24.3–
28.0] kg/m
2) was conducted. Participants received three therapeutic regimens for 2 consecutive
days: 1) 80 mg of oral prednisolone (PRED) every day (q.d.) and intravenous (IV) EXE infusion
(PRED+EXE); 2) 80 mg of oral PRED q.d. and IV saline infusion (PRED+SAL); and 3)o r a l
placebo-PRED q.d. and intravenous saline infusion (PLB+SAL). On day 1, glucose tolerance
was assessed during a meal challenge test. On day 2, participants underwent a clamp procedure
to measure insulin secretion and insulin sensitivity.
RESULTS—PRED+SAL treatment increased postprandial glucose levels (vs. PLB+SAL, P =
0.012), which was prevented by concomitant EXE (vs. PLB+SAL, P = NS). EXE reduced
PRED-induced hyperglucagonemia during the meal challenge (P = 0.018) and decreased gastric
emptying (vs. PRED+SAL, P = 0.028; vs. PLB+SAL, P = 0.046). PRED+SAL decreased ﬁrst-phase
glucose- and arginine-stimulated C-peptide secretion (vs. PLB+SAL, P =0 . 0 1 7a n dP =0 . 0 5 ,
respectively), whereas PRED+EXE improved ﬁrst- and second-phase glucose- and arginine-
stimulated C-peptide secretion (vs. PLB+SAL; P = 0.017, 0.012, and 0.093, respectively).
CONCLUSIONS—The GLP-1 RA EXE prevented PRED-induced glucose intolerance and
islet-cell dysfunction in healthy humans. Incretin-based therapies should be explored as a po-
tential strategy to prevent steroid diabetes.
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G
lucocorticoids (GCs) are diabeto-
genic agents because they reduce
insulin sensitivity (1), impair a-cell
function (2), and, according to more re-
cent ﬁndings, impair b-cell function
(3,4). As such, chronic use of GCs was
associated with odds ratios between 1.4
and2.3todevelop diabetes (5–7).Lossof
glycemic control during GC use is partic-
ularly due to impaired postprandial
glucose metabolism, whereas fasting
plasma glucose (FPG) levels are usually
only mildly elevated (4,7). Although the
exact prevalence of steroid-related diabe-
tes is unknown, the widespread use of
GCs indicates that it may represent a ma-
jor clinical problem worldwide.
When initiating GC therapy in cur-
rent clinical practice, preventive pharma-
cologic measures are taken to prevent
some of the GC-related side effects, most
notably osteoporosis and peptic ulcer
disease(8,9).Despitethehighlyprevalent
occurrence of steroid diabetes, to date, no
strategies have been undertaken to pre-
vent the adverse metabolic effects of GC
treatment. Previous studies showed that
metformin and the thiazolidinedione pio-
glitazone were unable to mitigate the ef-
fects of GCs on glucose tolerance (10),
whereas the thiazolidinedione troglita-
zone prevented GC-induced hyperglyce-
mia by enhancing GC clearance (10,11).
Because of liver toxicity, however, trogli-
tazoneisnolonger availablefor treatment
in humans.
The gut hormone glucagon-like pep-
tide (GLP)-1 and synthetic dipeptidyl-
peptidase-4 resistant GLP-1 receptor
agonists (GLP-1 RAs), such as exenatide
(EXE), lower blood glucose by, glucose-
dependently, enhancing insulin secretion
and production and inhibiting glucagon
secretion, and by slowing down gastric
emptying (12). One year of EXE treatment
was shown to improve clamp-measured
b-cell function in patients with type 2 di-
abetes mellitus (T2DM) (13). The GLP-1
RA exendin-4 was shown to prevent GC-
induced b-cell apoptosisinvitro (14). Ina
single patient with Cushing disease, GLP-1
infusionwasaseffectiveinloweringblood
glucose levels compar e dw i t hp a t i e n t s
with “typical” T2DM (15). GLP-1 infusion
effectively reduced stress hyperglycemia
inpatientsundergoingcoronaryarteryby-
pass grafting (16).
Given these beneﬁcial effects of GLP-1
RA treatment and the pathophysiologic
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Pathophysiology/Complications
ORIGINAL ARTICLEdefects underlying GC-induced glucose
intolerance and diabetes, we aimed to
assess whether intravenous (IV) infusion
of the GLP-1 RA EXE could prevent the
acute adverse effects of prednisolone
(PRED) treatment on glucose metabo-
lism, islet-cell function, and insulin sen-
sitivity in healthy normoglycemic
individuals.
RESEARCH DESIGN AND
METHODS
Participants
Eight healthy men were recruited via local
advertisements. Inclusion criteria included
age=18–35years,BMI=22.0–28.0kg/m
2,
goodphysicalhealth(determinedbymed-
ical history, physical examination, and
screening blood tests), and normoglyce-
mia as deﬁned by FPG ,5.6 mmol/L
and 2-h glucose ,7.8 mmol/L after a
75 g of oral glucose tolerance test per-
formed at the screening visit. Exclusion
criteria were the presence of any disease,
useofanymedication,ﬁrst-degree relative
with type 2 diabetes, smoking, shift
work, a history of GC use, and recent
changes in weight or physical activity.
The study was approved by an indepen-
dent ethics committee, and the study was
conducted in accordance with the Decla-
ration of Helsinki. All participants pro-
vided written informed consent before
participation.
Experimental design
The study was a randomized, placebo-
controlled, double-blind crossoverstudy.
After assessment of eligibility, partici-
pants received for 2 consecutive days, in
random order 1)8 0m go fo r a lP R E D
every day (q.d.) and IV EXE infusion
(PRED+EXE); 2)8 0m go r a lP R E Dq . d .
and IV saline infusion (PRED+SAL); and
3) oral placebo-PRED q.d. and IV saline
infusion (PLB+SAL). On day 1, a stan-
dardized meal challenge was performed
(Supplementary Fig. 1A). On day 2, par-
ticipants underwent a combined clamp
procedure, starting with a hyperinsuline-
mic-euglycemic clamp and followed by a
hyperglycemicclampwithsubsequentar-
ginine stimulation (Supplementary Fig.
1B) (13). The three 2-day treatment
blocks were separated by at least 4 weeks.
Participants were instructed to refrain
from intense physical activity 2 days be-
fore each treatment block.
The primary end point was the 4-h
glucose area under the curve (AUCG)
during the meal challenge test. From pre-
vious studies, we expected an increase in
AUCG of 400 mmol/L z 240 min after
PRED (4). A sample size of eight would
provide 80% power to detect a signiﬁcant
reduction of 50% by EXE of PRED-
inducedaugmentationofAUCG.Secondary
end points included ﬁrst- and second-
phase C-peptide incremental area under
thecurve(iAUCCP)andarginine-stimulated
C-peptide secretion (ASI-iAUCCP) during
the hyperglycemic clamp.
Standardized meal challenge
On day 1 of each treatment block, partic-
ipants underwent a standardized meal
challenge test after an overnight fast of
minimally 10 h. The meal contained 905
kcal (50 g fat, 75 g carbohydrates, 35 g
protein) and 1 g liquid acetaminophen
to estimate gastric emptying rates. Sam-
ples for determination of glucose, insulin,
C-peptide, glucagon, acetaminophen, and
EXE were obtained at times 2120, 260,
230, 0, 10, 20, 30, 60, 90, 120, 150, 180,
and 240 min, with the meal beginning
immediately after the time 0 sample and
consumed within 15 min. Eighty mg oral
PREDorPLBwasingested2hbefore meal
consumption and IV. EXE or SAL infu-
sion started 60 min before the meal at
an infusion rate of 40 ng/min for 30 min
a n dw a sd e c r e a s e dt o2 0n g / m i nf o r
the remainder of the test (Supplementary
Fig. 1A).
Hyperinsulinemic-euglycemic clamp
and hyperglycemic clamp
On day 2 of each block, a combined
hyperinsulinemic-euglycemic and hyper-
glycemic clamp procedure was done.
After an overnight fast, an indwelling
cannula was inserted into an antecubital
vein for infusion of glucose and insulin.
To obtain arterialized venous blood sam-
ples, a retrograde cannula was inserted
in a contralateral wrist vein and main-
tained in a heated box at 50°C. Insulin
w a si n f u s e da tar a t eo f4 0m U / m
2 z min
for 120 min; plasma glucose was kept at
5 mmol/L by a variable infusion of 20%
glucose. The hyperglycemic clamp was
started 90 min after cessation of exoge-
nous insulin infusion. Plasma glucose
concentration was then increased to 10
mmol/Lbyabody weight-adjustedIVbo-
lus of 20% glucose, and a variable 20%
glucoseinfusionwasadjustedtomaintain
the targeted glucose level. After 80 min of
hyperglycemia,anIVbolusof5garginine
(dissolved in 50 ml) was given over 45 s,
and the glucose level was maintained at
10 mmol/L for 30 min. Oral PRED or PLB
(80 mg) was administered 2 h before ini-
tiation of hyperinsulinemic-euglycemic
clamp. IV EXE or SAL infusion was
started 60 min before the start of the hy-
perglycemic clamp at an infusion rate of
40 ng/min for 30 min and was decreased
to 20 ng/min for the rest of the hypergly-
cemic clamp (Supplementary Fig. 1B).
Note that EXE was not infused during
the hyperinsulinemic-euglycemic clamp,
because in a pilot study, EXE strongly
induced insulin secretion at a glucose
level of 5 mmol/L. The hyperinsulinemic-
euglycemic clamp was performed to be
able to calculate the disposition index
(DI) (see below).
Study medication
PRED tablets were purchased from Pﬁzer
AB (Sollentuna, Sweden), and PLB tablets
were obtained from Xendo Drug Devel-
opment (Groningen, the Netherlands).
Tablets were capsulated to allow the
treatment to be blinded (4). Commer-
cially available EXE was purchased (Phar-
macy VU University Medical Center) and
diluted in saline containing 1% human
serum albumin, forming a colorless solu-
tion. IV administration of EXE was cho-
sen to be able to gain steady-state EXE
levels within a short period of time. The
plasma EXE target level was 100 pg/ml,
w h i c hd e m o n s t r a t e dg o o de f ﬁcacy and
tolerability during previous infusion ex-
periments (17).
Analytic determinations
Blood glucose concentrations were mea-
sured using an YSI 2300 STAT Plus
analyzer (YSI, Yellow Springs, OH). In-
sulin and C-peptide levels were deter-
mined using an immunometric assay
(Advia Centaur; Siemens Medical Solu-
tions Diagnostics, Deerﬁeld, IL). Gluca-
gon (Linco Research, St. Louis, MO) and
acetaminophen(AbbottLaboratories,Ab-
bott Park, IL) concentrations were de-
termined by radioimmunoassay. EXE
levels were determined by an immunoen-
zymetric assay as described previously
(Amylin, San Diego, CA) (17). Body fat
percentage was estimated by bioelectrical
impedance analysis (BF-906; Maltron In-
ternational, Rayleigh, Essex, UK).
Data analyses
Absolute area under the curves (AUCs)
for glucose, insulin, C-peptide, gluca-
gon, and acetaminophen were calculated
during the 4-h meal challenge using
the trapezoid method. The Matsuda
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van Raalte and Associateswhole-body insulin sensitivity index was
calculatedfromthemealchallenge.Whole-
body insulin sensitivity as obtained from
the hyperinsulinemic-euglycemic clamp
was quantiﬁed by the M-value, calculated
between min 90 and 120 during steady-
state insulin concentrations. iAUCCP for
the ﬁrst-phase (min 0–10) and second-
phase (min 10–80), and ASI-iAUCCP
(min 80–110) were calculated during the
hyperglycemic clamp using the trapezoid
method. The DI from the clamp tests was
calculated by the C-peptide iAUC multi-
plied by the M-value.
Statistical analyses
Dataare presented asmeanvalues6SEM
or, in case of skewed distribution, as me-
dian (interquartile range). Between-block
differencesweretestednonparametrically
with the Friedman test and, in case of a
signiﬁcant result, further analyzed using
the Wilcoxon signed-rank test. All statis-
tical analyses were run on SPSS (SPSS
I n c . ,C h i c a g o ,I L ) .AP , 0.05 was con-
sidered statistically signiﬁcant.
RESULTS
Subject characteristics
Eight healthy Caucasian men were in-
cluded, median (interquartile range):
age = 23.5 (20.0–28.3) years; BMI =
25.8 (23.2–27.7) kg/m
2;w a i s t=9 1( 8 2 –
95) cm; body fat = 21 (15–26) %; FPG =
5.0 (4.8–5.3) mmol/L; triglycerides = 1.1
(0.7–1.5) mmol/L; systolic blood pres-
sure = 119 (117–125) mmHg; diastolic
blood pressure = 77 (72–82) mmHg.
Standardized meal challenge
PRED+SAL treatment increased AUCG
compared with PLB+SAL (P = 0.012),
which was prevented by concomitant
EXE administration (Table 1, Fig. 1A).
AUC for insulin was not decreased by
PRED+SAL, although AUC for C-peptide
(AUCCP) tended to be lower (P = 0.07).
PRED+EXE signiﬁcantly decreased both
AUC for insulin and AUCCP (Table 1,
Fig. 1B and C). PRED+SAL nonsigniﬁ-
cantly increased glucagon secretion com-
pared with PLB+SAL (P = 0.09), which
was mitigated by EXE treatment (Fig.
1D). EXE signiﬁcantly decreased AUC for
acetaminophen compared with both PLB
and PRED, compatible with its gastric-
emptying slowing effects. The Matsuda
whole-body insulin sensitivity index in-
creased during EXE treatment compared
with PLB and PRED (Table 1).
Combined clamp procedure
C-peptide secretion, hyperglycemic
clamp. PRED decreased ﬁrst-phase
iAUCCP and ASI-iAUCCP (vs. PLB+SAL;
P =0 . 0 1 7a n dP = 0.05, respectively)
but did not affect second-phase iAUCCP
(Table 2). EXE restored PRED-induced
reductions in ﬁrst-phase iAUCCP and
ASI-iAUCCP,a n ds i g n i ﬁcantly improved
C-peptide secretion during the entire
clamp compared with PRED+SAL and
PLB+SAL (Table 2, Fig. 2A). Insulin
iAUC results were not different from
C-peptide iAUC results (Fig. 2B).
Insulin sensitivity, euglycemic clamp.
Insulin levels reached steady-state during
min 90–120 of the euglycemic clamp, av-
eraging 431 6 62 pmol/l (PLB+SAL),
418 6 73 pmol/l (PRED+SAL), and
422 6 57 pmol/l (PRED+EXE). PRED
acutely decreased the M-value obtained
from the euglycemic clamp by 20% (P =
0.018) (Fig. 2C). Adjustment of the
M-value by insulin levels during the
steady-state part of the clamp (M/I) did not
affecttheresults(datanotshown).Notethat
the effects of EXE on whole-body insulin
sensitivitywerenotassessedduringtheeu-
glycemic clamp; EXE was administered
during the hyperglycemic clamp only.
Disposition index
PRED+SAL decreased the DI from T = 0–
80minofthehyperglycemicclamp(com-
bined ﬁrst- and second-phase; P = 0.012)
and the DI from T = 80–110 min of the
hyperglycemic clamp (arginine stimula-
tion; P = 0.012). The PRED-induced de-
crease in DI was fully restored by
concomitant EXE infusion, and EXE sig-
niﬁcantly improved the DI compared
with PLB+SAL from T = 0–80 min (Fig.
2D and E).
EXE plasma levels/adverse effects
Mean EXE plasma levels equaled 65 6 4
pg/ml between T = 0 and T = 240 of the
meal challenge (Supplementary Fig. 2A)
and 80 6 4 pg/ml between T = 230 and
T = 110 of the hyperglycemic clamp
(Supplementary Fig. 2B). No adverse ef-
f e c t so fe i t h e rP R E Do rE X Et r e a t m e n t
wereexperienced by the participantsdur-
ing the meal or clamp procedure.
CONCLUSIONS—GCs are known to
impair glucose metabolism by inducing
insulin resistance and, more recently,
b-cell dysfunction (1,4). This study is
the ﬁrst to demonstrate that treatment
with the GLP-1RA EXE prevents PRED-
induced glucose intolerance as assessed
by a standardized meal challenge test.
Duringthehyperglycemicclamp,EXEin-
fusion restored PRED-induced impair-
ment of b-cell function variables and
even signiﬁcantly improved a number of
these variables relative to the control sit-
uation. In contrast with the ﬁndings ob-
served during the clamp procedure, EXE
treatmentgivenduringthemealchallenge
improved glucose tolerance but resulted
in decreased insulin plasma levels. This
observation is in line with a previous
study in healthy individuals in whom
subcutaneous EXE treatment reduced
postprandial glucose excursions despite
Table 1—Results from the standardized meal challenge
P value
PLB+SAL (N =8 ) P R E D + S A L( N = 8) PRED+EXE (N =8 )
PLB+SAL vs.
PRED+SAL
PLB+SAL vs.
PRED+EXE
PRED+SAL vs.
PRED+EXE
AUCG (mmol/L z 240 min) 1,199 (1,043–1,248) 1,335 (1,254–1,501) 1,247 (1,156–1,260) 0.012 0.263 0.025
AUCI (nmol/L z 240 min) 66.2 (35.2–81.0) 52.5 (27.2–70.2) 32.2 (22.8–40.1) 0.263 0.017 0.017
AUCCP (nmol/L z 240 min) 354 (212–382) 270 (191–328) 203 (184–221) 0.069 0.017 0.017
AUCGCG (pmol/L z 240 min) 2,845 (1,941–2,965) 3,085 (2,859–3,633) 2,232 (1,850–3,149) 0.091 0.499 0.018
AUCACET (mg/L z 240 min) 1,272 (1,002–1,485) 1,449 (1,243–1,542) 940 (801–1,039) 0.6 0.028 0.046
Matsuda index (no dimension) 22.6 (13.0–39.4) 20.4 (16.1–41.2) 36.8 (26.9–50.0) 0.575 0.025 0.012
AUCACET, acetaminophen area under the curve; AUCGCG, glucagon area under the curve; AUCI, insulin area under the curve.
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Glucocorticoids and GLP-1 receptor agonistssigniﬁcantlylowerinsulinlevels(18).The
glucose-lowering effects of EXE were at-
tributed to decreased glucagon secretion
and gastric emptying, and because of its
glucose-dependent mode of action, EXE
didnotfurtherstimulateinsulinsecretion
i nt h ep r e s e n c eo fn o r m o g l y c e m i a( 1 8 ) .
Our study similarly found reduced post-
prandial glucagon secretion and gastric
emptyingafterEXEtreatment.Studiesus-
ing stable isotope techniques have dem-
onstrated that EXE may also reduce
hepatic glucose output and increase
whole-body glucose disposal in the post-
prandial state, independently of its more
establishedeffectsonislethormonesecre-
tion and gastric emptying (19,20). In our
study, EXEimproved whole-body insulin
sensitivity during the meal challenge as
estimated by the Matsuda index; how-
ever, reduced glucose appearance result-
ing from decreased gastric emptying
seemed primarily responsible for improv-
ing glucose tolerance. We did not assess
the effects of EXE on whole-body insulin
sensitivity during the hyperinsulinemic-
euglycemic clamp for previous men-
tioned reasons.
In this proof-of-principle study, both
treatment regimens were administered
for a short period of time, that is, for 2
consecutive days per study block. Al-
though the acute metabolic effects of
both PRED and EXE may to some extent
differ from their effects after prolonged
administration, it provides a good model
Figure1—TheeffectofPREDwithorwithoutconcomitantEXEinfusiononplasmaglucose(A),insulin(B),C-peptide(C),andglucagon(D)levels
duringthemealchallenge.PREDincreasedAUCG,whichwaspreventedbyEXE(A),despitelowerinsulinandC-peptidelevels(B,C).EXEinfusion
reduced postprandial glucagon levels compared with PRED (D). Mean 6 SEM shown. Black solid line with closed squares: PLB+SAL; gray in-
tersected line with closed circles: PRED+SAL; black dotted line with open circles: PRED+EXE.
Table 2—Results from the hyperglycemic clamp
P value
PLB+SAL (N =8 ) P R E D + S A L( N =8 ) P R E D + E X E(N =8 )
PLB+SAL vs.
PRED+SAL
PLB+SAL vs.
PRED+EXE
PRED+SAL vs.
PRED+EXE
1st iAUCCP
6( 4 –8) 4 (2–6) 10 (8–13) 0.017 0.017 0.012 (nmol z min/L)
2nd iAUCCP
30 (17–48) 26 (18–53) 111 (63–117) 0.779 0.012 0.012 (nmol z min/L)
1st+2nd iAUCCP
83 (79–107) 71 (41–100) 201 (160–249) 0.208 0.012 0.012 (nmol z min/L)
ASI iAUCCP
26 (24–34) 18 (17–29) 37 (28–43) 0.05 0.093 0.012 (nmol z min/L)
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van Raalte and Associatesto study the effects of each of both drugs
andtheirinteraction.IVEXEinfusionwas
abletopreventtheacuteadverseeffectsof
PRED on glucose tolerance, and addi-
tional beneﬁts from EXE treatment may
be expected when both compounds are
administered for a more prolonged time
period.ChronicGCuseisassociatedwith
increased appetite, signiﬁcant weight
gain, increased visceral fat mass, altered
secretion of adipocytokines, and dyslipi-
demia (1), all of which contribute to the
adverse effects of GCs on glucose metab-
olism. In clinical studies in patients with
T2DM, chronic EXE treatment was
shown to reduce appetite, resulting in
substantial weight loss, decreased truncal
fat mass, and increased secretion of adi-
ponectin(13,21,22).Also,EXEimproved
postprandial dyslipidemia (23). The
strong reduction of postprandial glucose
levels by EXE, rather than a pronounced
effect on FPG (13), matches the proﬁle of
GC-inducedhyperglycemia,whichispre-
dominantly present during the day (7).
During the hyperglycemic clamp ex-
periments,pharmacologicconcentrations
o fE X Ew e r ea b l et or e s t o r eP R E D -
induced changes in b-cell function,
including ﬁrst-phase and ASI C-peptide
secretion and DI calculated for the entire
hyperglycemic clamp. GC exposure was
demonstrated to impair various pathways
in the b-cell in vitro. These include both
steps in the uptake and metabolism of
glucose, but GCs alsoaffected distal path-
ways in the insulin exocytosis process, re-
sulting in impaired insulin secretion in
response to different secretagogues
(3,4). Because EXE was able to restore in-
sulin secretion, one may speculate that
GCsdonotblockthepathwaysmediating
GLP-1 action on b-cells. However, it was
recently reported that a 2-week treatment
with oral PRED reduced the insulino-
tropic effects of endogenous GLP-1 and
glucose-dependent insulinotropic poly-
peptide (24).
A limitation of our study is that we
treated healthy subjects with GCs. GCs
are prescribed to treat acute and chronic
inﬂammatory diseases, as well as autoim-
mune diseases. Chronic inﬂammation is
also associated with whole-body insulin
resistance and b- c e l ld y s f u n c t i o n ,a sr e -
cently reported in patients with rheuma-
toidarthritis(25).Therefore,thecomplex
interrelationship among inﬂammation,
GC, and GLP-1RA treatment needs to be
studied prospectively in relevant patient
populations.
The plasma levels of EXE reached
with our infusion protocol were lower
than those usually obtained after subcu-
taneous injection of EXE 10 mg b.i.d. (the
recommended dose for the current treat-
ment in T2DM). Although good efﬁcacy
was demonstrated bycurrent plasmaEXE
levels,thefullpotentialofGLP-1RAtreat-
ment to prevent PRED-induced glucose
intolerance may be fully unveiled in clin-
ical studies administering EXE at the
usual dose.
This study provides evidence that the
GLP-1 RA EXE may prevent PRED-
induced glucose intolerance and restore
islet-cell functional balance. Long-term
studies in relevant populations should
explore the potential of GLP-1 RA treat-
mentasanovelstrategytopreventsteroid
diabetes.
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